Physician profile
Nadeem Tajuddin
NPI 1063830230
$6,468.06
in general payments reported to CMS, 2019-2025
44 companies · $904 in 2025
The $904 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,637 · 2020: $670 · 2021: $538 · 2022: $682 · 2023: $952 · 2024: $1,085 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,940.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $775.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $770.06 | 2019-2024 | |
| Amarin Pharma, INC. | $638.93 | 2019-2023 | |
| Amgen INC. | $602.65 | 2019-2025 | Evenity, Prolia, Prolia |
| Lilly USA, LLC | $405.02 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $374.72 | 2019-2023 | Saphnelo, Farxiga |
| Merck Sharp & Dohme LLC | $271.17 | 2019-2023 | Steglujan, Steglatro |
| Janssen Biotech, INC. | $210.74 | 2019-2025 | Tremfya |
| Intuity Medical INC | $192.83 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Bayer Healthcare Pharmaceuticals INC. | $184.16 | 2023-2025 | |
| Dexcom, INC. | $178.29 | 2020-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $166.70 | 2024-2025 | Omnipod |
| Corcept Therapeutics | $132.43 | 2023-2025 | Korlym |
| Ibsa Pharma INC. | $124.85 | 2020-2025 | Tirosint, Tirosint, Licart |
| Antares Pharma, INC. | $124.19 | 2022-2025 | Xyosted, Tlando, Nocdurna |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadeem Tajuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.